Search
Back

Voclosporin

CAS 515814-01-4
Voclosporin

General Information

In its finished dose, Voclosporin is indicated for the treatment of certain autoimmune diseases, with its primary application being for the management of lupus nephritis. Its mechanism of action inhibits the activation of T cells in the immune system, helping to reduce inflammation and the immune response in conditions like lupus nephritis. Voclosporin is typically used in combination with other medications.


About the API

Technology Fermentation
Therapeutic category Antineoplastic and Immunomodulating Agents
Systematic Name (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.